{"id":24289,"date":"2024-05-13T10:12:31","date_gmt":"2024-05-13T08:12:31","guid":{"rendered":"https:\/\/ggba.swiss\/ikerian-parent-company-of-retinai-secures-usd-6-18-million-for-ai-driven-medical-advancements\/"},"modified":"2024-05-13T10:15:06","modified_gmt":"2024-05-13T08:15:06","slug":"ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/","title":{"rendered":"Ikerian, soci\u00e9t\u00e9 m\u00e8re de RetinAI, l\u00e8ve USD 6,18 millions pour des avanc\u00e9es m\u00e9dicales bas\u00e9es sur l’IA"},"content":{"rendered":"\n

Fond\u00e9e en 2016 et bas\u00e9e \u00e0 Berne, RetinAI<\/a> d\u00e9veloppe des outils logiciels qui exploitent l’apprentissage automatique pour g\u00e9rer et analyser efficacement les donn\u00e9es d’imagerie m\u00e9dicale. La mission de l’entreprise est de transformer le diagnostic et le traitement des maladies oculaires telles que la d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l’\u00e2ge, la r\u00e9tinopathie diab\u00e9tique et le glaucome gr\u00e2ce \u00e0 des solutions innovantes pilot\u00e9es par l’IA qui am\u00e9liorent la d\u00e9tection pr\u00e9coce et facilitent la gestion continue de la maladie.<\/p>\n\n\n\n

Le dernier tour de table de la soci\u00e9t\u00e9 m\u00e8re de RetinAI, Ikerian, a \u00e9t\u00e9 men\u00e9 par la branche Corporate Venture Capital de Topcon Healthcare, Inc<\/a>. avec des contributions significatives de la Z\u00fcrcher Kantonalbank (ZKB) et de partenaires de longue date, dont le fonds btov Industrial Technologies g\u00e9r\u00e9 par Matterwave Ventures<\/a>, Verve Ventures<\/a>, et divers investisseurs priv\u00e9s. Cette injection strat\u00e9gique de capital facilitera l’expansion d’Ikerian dans de nouveaux domaines th\u00e9rapeutiques tels que les troubles neurod\u00e9g\u00e9n\u00e9ratifs, les affections vasculaires et les maladies rares, tout en continuant \u00e0 renforcer son travail de pionnier en ophtalmologie et en optom\u00e9trie gr\u00e2ce \u00e0 RetinAI.<\/p>\n\n\n\n

RetinAI, connue pour son application de pointe de l’IA dans les diagnostics ophtalmologiques, a \u00e9t\u00e9 un pr\u00e9curseur dans la transformation des flux de travail de la recherche clinique et pharmaceutique. \u00ab Le succ\u00e8s de ce tour de table confirme l’importance de notre technologie d’IA pour r\u00e9inventer les flux de travail de la recherche clinique et pharmaceutique afin de favoriser une prise en charge plus efficace des patients \u00bb, a d\u00e9clar\u00e9 le Dr Carlos Ciller, CEO et Pr\u00e9sident d’Ikerian et de RetinAI.<\/p>\n\n\n\n

Un bond en avant dans l’utilisation de l’IA pour les soins de sant\u00e9<\/h4>\n\n\n\n

Les fonds soutiendront notamment les efforts de d\u00e9veloppement de la plateforme Discovery de RetinAI et de son pipeline complet de technologies d’IA. Il s’agit notamment d’\u00e9largir la base de donn\u00e9es Real-World Evidence (RWE) \u00e0 diverses maladies oculaires telles que l’atrophie g\u00e9ographique (GA), la d\u00e9g\u00e9n\u00e9rescence maculaire n\u00e9ovasculaire li\u00e9e \u00e0 l’\u00e2ge (nAMD) et la r\u00e9tinopathie diab\u00e9tique (DR), renfor\u00e7ant ainsi la capacit\u00e9 de l’entreprise \u00e0 soutenir la recherche pharmaceutique et clinique.<\/p>\n\n\n\n

Le Dr Sandro De Zanet, directeur scientifique d’Ikerian et de RetinAI, a soulign\u00e9 l’importance strat\u00e9gique des connaissances de la soci\u00e9t\u00e9 en mati\u00e8re de RWE. \u00ab Le fait de disposer d’un portefeuille d’insights RWE permet \u00e0 RetinAI d’offrir une valeur encore plus grande aux entreprises pharmaceutiques en acc\u00e9l\u00e9rant les \u00e9tudes cliniques et en enrichissant l’analyse des donn\u00e9es bas\u00e9e sur l’IA pour soutenir les traitements futurs \u00bb, a-t-il expliqu\u00e9. L’outil Discovery et les biomarqueurs IA d\u00e9velopp\u00e9s par RetinAI devraient r\u00e9volutionner le d\u00e9pistage et l’analyse des patients \u00e0 travers de vastes ensembles de donn\u00e9es d’imagerie, simplifiant ainsi les processus d’essais cliniques.<\/p>\n","protected":false},"excerpt":{"rendered":"

Ikerian AG et sa filiale RetinAI ont conclu avec succ\u00e8s un tour de financement de s\u00e9rie A d’un montant de USD 6,18 millions afin de propulser le d\u00e9veloppement et le d\u00e9ploiement commercial de technologies m\u00e9dicales innovantes.<\/p>\n","protected":false},"author":6,"featured_media":24286,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1179,1180,1148,1251,1171],"class_list":["post-24289","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-artificial-intelligence-fr-2","tag-digital-health-fr-2","tag-financing-fr-2","tag-imaging-fr-2","tag-pharma-fr-2"],"acf":[],"yoast_head":"\nRetinAI l\u00e8ve USD 6,18 millions | GGBa<\/title>\n<meta name=\"description\" content=\"RetinAI a lev\u00e9 USD 6,18 millions afin de propulser le d\u00e9veloppement et le d\u00e9ploiement commercial de technologies m\u00e9dicales innovantes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RetinAI l\u00e8ve USD 6,18 millions | GGBa\" \/>\n<meta property=\"og:description\" content=\"RetinAI a lev\u00e9 USD 6,18 millions afin de propulser le d\u00e9veloppement et le d\u00e9ploiement commercial de technologies m\u00e9dicales innovantes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-13T08:12:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-13T08:15:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/retinAI-Ikerian-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Ikerian, soci\u00e9t\u00e9 m\u00e8re de RetinAI, l\u00e8ve USD 6,18 millions pour des avanc\u00e9es m\u00e9dicales bas\u00e9es sur l’IA\",\"datePublished\":\"2024-05-13T08:12:31+00:00\",\"dateModified\":\"2024-05-13T08:15:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/\"},\"wordCount\":527,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/retinAI-Ikerian-1180x811-1.jpeg\",\"keywords\":[\"Artificial Intelligence\",\"Digital Health\",\"Financing\",\"Imaging\",\"Pharma\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/\",\"name\":\"RetinAI l\u00e8ve USD 6,18 millions | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/retinAI-Ikerian-1180x811-1.jpeg\",\"datePublished\":\"2024-05-13T08:12:31+00:00\",\"dateModified\":\"2024-05-13T08:15:06+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"RetinAI a lev\u00e9 USD 6,18 millions afin de propulser le d\u00e9veloppement et le d\u00e9ploiement commercial de technologies m\u00e9dicales innovantes.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/retinAI-Ikerian-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/retinAI-Ikerian-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"De gauche \u00e0 droite : Carlos Ciller, PhD, CEO, cofondateur et pr\u00e9sident d'Ikerian AG et de RetinAI US Inc ; Stefanos Apostolopoulos, PhD, CTO et cofondateur d'Ikerian AG et de RetinAI US Inc ; Sandro De Zanet, PhD, Chief Scientific Officer et cofondateur d'Ikerian AG et de RetinAI US Inc. | \u00a9 RetinAI\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ikerian, soci\u00e9t\u00e9 m\u00e8re de RetinAI, l\u00e8ve USD 6,18 millions pour des avanc\u00e9es m\u00e9dicales bas\u00e9es sur l’IA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RetinAI l\u00e8ve USD 6,18 millions | GGBa","description":"RetinAI a lev\u00e9 USD 6,18 millions afin de propulser le d\u00e9veloppement et le d\u00e9ploiement commercial de technologies m\u00e9dicales innovantes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/","og_locale":"fr_FR","og_type":"article","og_title":"RetinAI l\u00e8ve USD 6,18 millions | GGBa","og_description":"RetinAI a lev\u00e9 USD 6,18 millions afin de propulser le d\u00e9veloppement et le d\u00e9ploiement commercial de technologies m\u00e9dicales innovantes.","og_url":"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-05-13T08:12:31+00:00","article_modified_time":"2024-05-13T08:15:06+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/retinAI-Ikerian-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Ikerian, soci\u00e9t\u00e9 m\u00e8re de RetinAI, l\u00e8ve USD 6,18 millions pour des avanc\u00e9es m\u00e9dicales bas\u00e9es sur l’IA","datePublished":"2024-05-13T08:12:31+00:00","dateModified":"2024-05-13T08:15:06+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/"},"wordCount":527,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/retinAI-Ikerian-1180x811-1.jpeg","keywords":["Artificial Intelligence","Digital Health","Financing","Imaging","Pharma"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/","url":"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/","name":"RetinAI l\u00e8ve USD 6,18 millions | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/retinAI-Ikerian-1180x811-1.jpeg","datePublished":"2024-05-13T08:12:31+00:00","dateModified":"2024-05-13T08:15:06+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"RetinAI a lev\u00e9 USD 6,18 millions afin de propulser le d\u00e9veloppement et le d\u00e9ploiement commercial de technologies m\u00e9dicales innovantes.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/retinAI-Ikerian-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/retinAI-Ikerian-1180x811-1.jpeg","width":1180,"height":811,"caption":"De gauche \u00e0 droite : Carlos Ciller, PhD, CEO, cofondateur et pr\u00e9sident d'Ikerian AG et de RetinAI US Inc ; Stefanos Apostolopoulos, PhD, CTO et cofondateur d'Ikerian AG et de RetinAI US Inc ; Sandro De Zanet, PhD, Chief Scientific Officer et cofondateur d'Ikerian AG et de RetinAI US Inc. | \u00a9 RetinAI"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/ikerian-societe-mere-de-retinai-leve-usd-618-millions-pour-des-avancees-medicales-basees-sur-lia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Ikerian, soci\u00e9t\u00e9 m\u00e8re de RetinAI, l\u00e8ve USD 6,18 millions pour des avanc\u00e9es m\u00e9dicales bas\u00e9es sur l’IA"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/24289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=24289"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/24289\/revisions"}],"predecessor-version":[{"id":24291,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/24289\/revisions\/24291"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/24286"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=24289"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=24289"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=24289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}